When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SNGX - Soligenix completes enrollment in late-stage study of dusquetide for oral mucositis
Soligenix Inc.
Soligenix (NASDAQ:SNGX) has hit the enrollment target of 268 subjects in a Phase 3 clinical trial, DOM-INNATE, evaluating SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer, a debilitating inflammatory condition caused by cancer treatments (radiation, for example).
More news on: Soligenix, Inc., Healthcare stocks news, Stocks on the move,